A multicenter randomized comparative study to know the effects of atorvastatin on the plaque stability before carotid artery stenting

A multicenter randomized comparative study to know the effects of atorvastatin on the plaque stability before carotid artery stenting - Atorvastatin Before Carotid Artery Stenting(AB-CAS) Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006060

Enrollment

200

Registered

2011-09-01

Start date

2011-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

carotid artery stenosis

Interventions

Atorvastatin 20mg/day for 4 weeks before carotid artery stenting and 12 weeks after carotid artery stenting Medical treatment without atorvastatin for 4 weeks before carotid artery stenting and 12 we

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria 1)Patient whose age is between 20 and 80 years 2)LDL-cholesterol < 160mg/dL 3)The patients with symptomatic stenosis (>=50%) or asymptomatic stenosis (>=80%) who is eligible for carotid artery stenting 4)Patient who signed an informed consent form

Exclusion criteria

Exclusion criteria: Exclusion criteria 1)Patients who were administrated statins within a month 2)Patients who have liver dysfunction (ALT and/or AST > 100IU/L) 3)Patients who have kidney dysfunction (serum creatinine > 1.5 mg/dL) 4)Patients who have history of allergy to statins 5)Women who is wishing a baby, pregnant or nursing 6)Patients who are inappropriate to participate in this study

Design outcomes

Primary

Measure	Time frame
Number of newly appeared high intensity spots on the diffusion weighted MRI(DW-MRI) within 3 days after CAS	—

Secondary

Measure	Time frame
1)Plaque quality change on MRI plaque imaging during operation waiting period 2)Changes of maximum intima-media complex thickness(IMT) and peak systolic velocity(PSV) on carotid duplex scan during operation waiting period 3)Volume of new high intensity spots on the DW-MRI performed 1-3 days after CAS 4)Serum lipid change(Total cholesterol,HDL-C,triglyceride and LDL-C) 5)Incidence of major cardiovascular events(non-fatal myocardial infarction,stroke,cardiovascular death and revascularization) until 12 weeks after CAS	—

Measure

Time frame

1)Plaque quality change on MRI plaque imaging during operation waiting period 2)Changes of maximum intima-media complex thickness(IMT) and peak systolic velocity(PSV) on carotid duplex scan during operation waiting period 3)Volume of new high intensity spots on the DW-MRI performed 1-3 days after CAS 4)Serum lipid change(Total cholesterol,HDL-C,triglyceride and LDL-C) 5)Incidence of major cardiovascular events(non-fatal myocardial infarction,stroke,cardiovascular death and revascularization) until 12 weeks after CAS

—

Countries

Japan

Contacts

Public ContactShinichi Yoshimura

Hyogo College of Medicine Department of Neurosurgery

s-yoshi@hyo-med.ac.jp+81-798-45-6455

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026